Estimated  	Estimated  	 JJ	B-NP
mortality  	mortality  	 NN	I-NP
of  	of  	 IN	O
adult  	adult  	 JJ	O
HIV-infected  	HIV-infected  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
starting  	starting  	 VBG	I-NP
treatment  	treatment  	 NN	I-NP
with  	with  	 IN	O
combination  	combination  	 NN	B-NP
antiretroviral  	antiretroviral  	 NN	I-NP
therapy  	therapy  	 NN	I-NP
To  	To  	 TO	O
provide  	provide  	 VB	O
estimates  	estimates  	 NNS	O
of  	of  	 IN	O
mortality  	mortality  	 NN	O
among  	among  	 IN	O
HIV-infected  	HIV-infected  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
starting  	starting  	 VBG	I-NP
combination  	combination  	 NN	I-NP
antiretroviral  	antiretroviral  	 NN	I-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
report  	report  	 VBP	O
on  	on  	 IN	O
the  	the  	 DT	O
death  	death  	 NN	B-NP
rates  	rates  	 NNS	I-NP
from  	from  	 IN	O
122  	122  	 CD	O
925  	925  	 CD	O
adult  	adult  	 NN	B-NP
HIV-infected  	HIV-infected  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
aged  	aged  	 VBN	O
15  	15  	 CD	O
years  	years  	 NNS	O
or  	or  	 CC	O
older  	older  	 JJR	O
from  	from  	 IN	O
East 	East 	 NNP	O
,  	,  	 ,	O
Southern  	Southern  	 NNP	O
and  	and  	 CC	O
West  	West  	 NNP	O
Africa 	Africa 	 NNP	O
,  	,  	 ,	O
Asia  	Asia  	 NNP	O
Pacific  	Pacific  	 NNP	O
and  	and  	 CC	O
Latin  	Latin  	 NNP	O
America 	America 	 NNP	O
.  	.  	 .	O
We  	We  	 PRP	O
use  	use  	 VBP	O
two  	two  	 CD	O
methods  	methods  	 NNS	O
to  	to  	 TO	O
adjust  	adjust  	 VB	O
for  	for  	 IN	O
biases  	biases  	 NNS	O
in  	in  	 IN	O
mortality  	mortality  	 NN	B-NP
estimation  	estimation  	 VBZ	I-NP
resulting  	resulting  	 VBG	O
from  	from  	 IN	O
loss  	loss  	 NN	O
from  	from  	 IN	O
follow-up 	follow-up 	 NNP	O
,  	,  	 ,	O
based  	based  	 VBN	O
on  	on  	 IN	O
double-sampling  	double-sampling  	 JJ	O
methods  	methods  	 NNS	O
applied  	applied  	 VBN	O
to  	to  	 TO	O
patient  	patient  	 JJ	O
outreach  	outreach  	 NNS	B-NP
( 	( 	 -LRB-	O
Kenya 	Kenya 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
linkage  	linkage  	 NN	O
with  	with  	 IN	O
vital  	vital  	 JJ	O
registries  	registries  	 NNS	O
( 	( 	 -LRB-	O
South  	South  	 NNP	O
Africa 	Africa 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
apply  	apply  	 VB	O
these  	these  	 DT	O
to  	to  	 TO	O
mortality  	mortality  	 NN	B-NP
estimates  	estimates  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
other  	other  	 JJ	O
three  	three  	 CD	O
regions 	regions 	 NNS	O
.  	.  	 .	O
Age 	Age 	 NN	O
,  	,  	 ,	O
gender  	gender  	 NN	B-NP
and  	and  	 CC	O
CD4  	CD4  	 CD	B-NP
count  	count  	 NN	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
initiation  	initiation  	 NN	O
of  	of  	 IN	O
therapy  	therapy  	 NN	O
were  	were  	 VBD	O
the  	the  	 DT	O
factors  	factors  	 NNS	O
considered  	considered  	 VBN	O
as  	as  	 IN	O
predictors  	predictors  	 NN	O
of  	of  	 IN	O
mortality  	mortality  	 NN	O
at  	at  	 IN	O
6 	6 	 CD	O
,  	,  	 ,	O
12 	12 	 CD	O
,  	,  	 ,	O
24  	24  	 CD	O
and  	and  	 CC	O
> 	> 	 CD	O
24  	24  	 CD	O
months  	months  	 NNS	O
after  	after  	 IN	O
the  	the  	 DT	O
start  	start  	 NN	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
Patient  	Patient  	 JJ	O
mortality  	mortality  	 NN	O
was  	was  	 VBD	O
high  	high  	 JJ	O
during  	during  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
6  	6  	 CD	O
months  	months  	 NNS	O
after  	after  	 IN	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
all  	all  	 DT	O
patient  	patient  	 JJ	O
subgroups  	subgroups  	 NNS	B-NP
and  	and  	 CC	O
exceeded  	exceeded  	 VBD	O
40  	40  	 CD	O
per  	per  	 IN	O
100  	100  	 CD	O
patient  	patient  	 NN	O
years  	years  	 NNS	O
among  	among  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
started  	started  	 VBD	B-NP
treatment  	treatment  	 NN	I-NP
at  	at  	 IN	O
low  	low  	 JJ	O
CD4  	CD4  	 CD	B-NP
count 	count 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
trend  	trend  	 NN	O
was  	was  	 VBD	O
seen  	seen  	 VBN	O
regardless  	regardless  	 RB	O
of  	of  	 IN	O
region 	region 	 NN	O
,  	,  	 ,	O
demographic  	demographic  	 JJ	B-NP
or  	or  	 CC	O
disease-related  	disease-related  	 JJ	O
risk  	risk  	 NN	B-NP
factor 	factor 	 NN	I-NP
.  	.  	 .	O
Mortality  	Mortality  	 NN	O
was  	was  	 VBD	O
under-reported  	under-reported  	 JJ	O
by  	by  	 IN	O
up  	up  	 RB	O
to  	to  	 TO	O
or  	or  	 CC	O
exceeding  	exceeding  	 VBG	O
100 	100 	 CD	O
%  	%  	 NN	O
when  	when  	 WRB	O
comparing  	comparing  	 JJ	O
estimates  	estimates  	 NNS	O
obtained  	obtained  	 VBN	O
from  	from  	 IN	O
passive  	passive  	 JJ	B-NP
monitoring  	monitoring  	 NN	I-NP
of  	of  	 IN	O
patient  	patient  	 JJ	O
vital  	vital  	 JJ	O
status 	status 	 NN	O
.  	.  	 .	O
Despite  	Despite  	 IN	O
advances  	advances  	 NNS	O
in  	in  	 IN	O
antiretroviral  	antiretroviral  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
coverage  	coverage  	 NN	I-NP
many  	many  	 JJ	O
patients  	patients  	 NNS	O
start  	start  	 VBP	O
treatment  	treatment  	 NN	O
at  	at  	 IN	O
very  	very  	 RB	O
low  	low  	 JJ	O
CD4  	CD4  	 CD	B-NP
counts  	counts  	 NNS	I-NP
and  	and  	 CC	O
experience  	experience  	 VB	O
significant  	significant  	 JJ	O
mortality  	mortality  	 NN	O
during  	during  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
6  	6  	 CD	O
months  	months  	 NNS	O
after  	after  	 IN	O
treatment  	treatment  	 NN	B-NP
initiation 	initiation 	 NN	I-NP
.  	.  	 .	O
Active  	Active  	 JJ	O
patient  	patient  	 NN	O
tracing  	tracing  	 NNS	O
and  	and  	 CC	O
linkage  	linkage  	 NN	O
with  	with  	 IN	O
vital  	vital  	 JJ	O
registries  	registries  	 NNS	O
are  	are  	 VBP	O
critical  	critical  	 JJ	O
in  	in  	 IN	O
adjusting  	adjusting  	 VBG	B-NP
estimates  	estimates  	 NNS	I-NP
of  	of  	 IN	O
mortality 	mortality 	 NN	O
,  	,  	 ,	O
particularly  	particularly  	 RB	O
in  	in  	 IN	O
low-  	low-  	 JJ	O
and  	and  	 CC	O
middle-income  	middle-income  	 JJ	B-NP
settings 	settings 	 NNS	I-NP
.  	.  	 .	O
